Editor´s choice articles 2006–2008

• References

• 1 Essayagh S, Xuereb JM, Terrisse AD. et al. Microparticles from apoptotic monocytes induce transient platelet recruitment and tissue factor expression by cultured human vascular endothelial cells via a redoxsensitive mechanism. Thromb Haemost 2007; 98: 831-837.
• 2 Sinauridze EI, Kireev DA, Popenko NY. et al. Platelet microparticle membranes have 50-to 100-fold higher specific procoagulant activity than activated platelets. Thromb Haemost 2007; 97: 425-434.
• 3 Hron G, Kollars M, Weber H. et al. Tissue factorpositive microparticles: Cellular origin and association with coagulation activation in patients with colorectal cancer. Thromb Haemost 2007; 97: 119-123.
• 4 Ludwig RJ, Alban S, Bistrian R. et al. The ability of different forms of heparins to suppress P-selectin function in vitro correlates to their inhibitory capacity on bloodborne metastasis in vivo . Thromb Haemost 2006; 95: 535-540.
• 5 Oldenburg J, Bevans CG, Fregin A. et al. Current pharmacogenetic developments in oral anticoagulation therapy: The influence of variant VKORC1 and CYP2C9 alleles. Thromb Haemost 2007; 98: 570-578.
• 6 Vecsler M, Loebstein R, Almog S. et al. Combined genetic profiles of components and regulators of the vitamin K-dependent γ-carboxylation system affect individual sensitivity to warfarin. Thromb Haemost 2006; 95: 205-211.
• 7 Herman D, Peternel P, Stegnar M. et al. The influence of sequence variations in factor VII, γ -glutamyl carboxylase and vitamin K epoxide reductase complex genes on warfarin dose requirement. Thromb Haemost 2006; 95: 782-787.
• 8 Kerdudou S, Laschke MW, Sinha B. et al. Fibronectin binding proteins contribute to the adherence of Staphylococcus aureus to intact endothelium in vivo . Thromb Haemost 2006; 96: 183-189.
• 9 de Waard V, Hansen HR, Spronk HH. et al. Differential expression of tissue factor mRNA and protein expression in murine sepsis. The role of the granulocyte revisited. Thromb Haemost 2006; 95: 348-353.
• 10 Pullamsetti SS, Maring D, Ghofrani HA. et al. Effect of nitric oxide synthase (NOS) inhibition on macro and microcirculation in a model of rat endotoxic shock. Thromb Haemost 2006; 95: 720-727.
• 11 Hoffmann JN, Wiedermann CJ, Juers M. et al. Benefit/risk profile of high-dose antithrombin in patients with severe sepsis treated with and without concomitant heparin. Thromb Haemost 2006; 95: 850-856.
• 12 Lev EI, Estrov Z, Aboulfatova K. et al. Potential role of activated platelets in homing of human endothelial progenitor cells to subendothelial matrix. Thromb Haemost 2006; 96: 498-504.
• 13 Toth O, Calatzis A, Penz S. et al. Multiple electrode aggregometry: A new device to measure platelet aggregation in whole blood. Thromb Haemost 2006; 96: 781-788.
• 14 Dovlatova N, Wijeyeratne YD, Fox SC. et al. Detection of P2Y14 protein in platelets and investigation of the role of P2Y14 in platelet function in comparison with the EP3 receptor. Thromb Haemost 2008; 100: 261-270.
• 15 Neubauer H, Lask S, Engelhardt A. et al. How to optimise clopidogrel therapy? Reducing the low-response incidence by aggregometry-guided therapy modification. Thromb Haemost 2008; 99: 357-362.
• 16 Wadanoli M, Sako D, Shaw GD. et al. The von Willebrand factor antagonist (GPG-290) prevents coronary thrombosis without prolongation of bleeding time. Thromb Haemost 2007; 98: 397-405.
• 17 Penz SM, Reininger AJ, Toth O. et al. Glycoprotein Ibalpha inhibition and ADP receptor antagonists, but not aspirin, reduce platelet thrombus formation in flowing blood exposed to atherosclerotic plaques. Thromb Haemost 2007; 97: 435-443.
• 18 Babinska A, Azari BM, Salifu MO. et al. The F11 receptor (F11R/JAM-A) in atherothrombosis: overexpression of F11R in atherosclerotic plaques. Thromb Haemost 2007; 97: 272-281.
• 19 Sachais BS, Turrentine T, Dawicki McKenna JM. et al. Elimination of platelet factor 4 (PF4) from platelets reduces atherosclerosis in C57Bl/6 and apoE−/−mice. Thromb Haemost 2007; 98: 1108-1113.